Nu Skin Files 8-K on Financials & Officer Changes

TL;DR

**Nu Skin just dropped an 8-K about financials and officer changes, keep an eye out for details!**

AI Summary

Nu Skin Enterprises, Inc. filed an 8-K on February 14, 2024, reporting events that occurred on February 9, 2024. The filing indicates updates regarding the company's financial condition and results of operations. Additionally, it addresses potential changes in directors or officers and their compensatory arrangements, though specific names, dollar amounts, or detailed events are not provided in this excerpt.

Why It Matters

This filing signals potential shifts in Nu Skin's financial performance and leadership structure, which could impact future strategic direction and investor confidence.

Risk Assessment

Risk Level: medium — Changes in financial condition and officer appointments/departures can introduce uncertainty or significant strategic shifts for a company.

Key Players & Entities

• NU SKIN ENTERPRISES, INC. (company) — registrant
• Gregory Belliston (person) — contact person for business/mail address

FAQ

Filing Documents

• ef20021676_8k.htm (8-K) — 31KB
• ef20021676_ex99-1.htm (EX-99.1) — 563KB
• image00001.jpg (GRAPHIC) — 4KB
• 0001140361-24-007981.txt ( ) — 765KB
• nus-20240209.xsd (EX-101.SCH) — 4KB
• nus-20240209_lab.xml (EX-101.LAB) — 22KB
• nus-20240209_pre.xml (EX-101.PRE) — 16KB
• ef20021676_8k_htm.xml (XML) — 4KB

02

Item 2.02 Results of Operations and Financial Condition. On February 14, 2024, Nu Skin Enterprises, Inc. (the "Company") issued a press release announcing its financial results for the three-month and annual periods ended December 31, 2023, and certain other information. A copy of the press release is attached as Exhibit 99.1 to this report. The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 9, 2024, Joseph Chang informed Nu Skin Enterprises, Inc. (the "Company") that he will be stepping down from his role as Chief Scientific Officer as of March 30, 2024. It is anticipated that he will transition to leading the Company's Scientific Advisory Board. On February 10, 2024, the Company's Board of Directors determined that the Chief Scientific Officer role is no longer an executive officer position. The Company and its management wish to express their appreciation to Dr. Chang for the important contributions he has made since joining the Company more than 20 years ago, and they look forward to his continued involvement with the Company.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. 99.1 Nu Skin Enterprises' press release dated February 14, 2024, regarding financial results for the three-month and annual periods ended December 31, 2023. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NU SKIN ENTERPRISES, INC. (Registrant) /s/ James D. Thomas James D. Thomas Chief Financial Officer Date: February 14, 2024

View Full Filing

View this 8-K filing on SEC EDGAR